Skip to main content

Advertisement

Table 1 Clinical features of patients in the 2D-DIGE discovery experiment

From: Predicting response to vascular endothelial growth factor inhibitor and chemotherapy in metastatic colorectal cancer

Clinical features Responders (n = 11) Non responders (n = 12)
Age (range, years) 61 (47-74) 58 (29-71)
Gender (male/female) 7/4 4/8
Site   
Ascending colon 1 (9.%) 2 (16.7%)
Descending colon 3 (27.3%) 1 (8.3%)
Tranverse colon 0 1 (8.3%)
Sigmoid colon 5 (45.5%) 4 (33.3%)
Rectum 2 (18.2%) 4 (33.3%)
Stage of CRC at diagnosis   
Stage I 0 0
Stage II 0 0
Stage III 1 (9.1%) 0
Stage IV 10 (90.9%) 12 (100%)
Differentiation   
Well 1 (9.1%) 1 (8.3%)
Moderately 8 (72.7%) 5 (41.7%)
Poorly 1 (9.1%) 2 (16.7%)
Unknown 1 (9.1%) 4 (33.3%)
Previous chemotherapy in Neoadjuvant/Adjuvant setting   
Yes 0 0
No 11 (100%) 12 (100%)
Chemotherapy for mCRC   
FOLFOX/FLOX 4 (36.4%) 6 (50%)
FOLFIRI 2 (18.2%) 0
Xelox 4 (36.4%) 6 (50%)
5FU/Xeloda 1 (9%) 0
Maintenance bevacizumab   
Yes 4 (36.4%) 4 (33.3%)
No 7 (63.6%) 8 (66.7%)
PFS, median (range, days) 345 (301-720) 208 (93-260)
Duration of bevacizumab treatment, median, days, range 363 (138-880) 207 (83-460)